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The International Prostate Symptoms Score (IPSS) questionnaire has been used for decades to evaluate
the severity of lower urinary tract symptoms (LUTS)/benign prostatic obstruction, and has also been
applied to other conditions causing LUTS. However, the total IPSS correlates poorly with benign prostatic
obstruction and overactive bladder, and is unreliable for establishing a deﬁnitive diagnosis. Although the
clinical symptoms are not reliable in establishing the diagnosis, patients with bladder outlet-related
lower urinary tract disease (LUTD) tend to have more prominent voiding symptoms and those with
bladder-related LUTD tend to have more prominent storage symptoms. Measuring IPSS subscores and
calculating the IPSS voiding-to-storage subscore ratio (IPSS-V/S) constitute a simple and reliable method
to differentiate failure-to-void (bladder outlet-related) LUTD from failure-to-storage (bladder-related)
LUTD. The IPSS-V/S is a better predictor of bladder outlet-related LUTD than the total IPSS, whether used
alone or in combination with the total prostate volume and maximal ﬂow rate. The IPSS-V/S can also be
used as a guide for the initial treatment of male LUTS, especially by nonurologists. First-line anti-
muscarinic monotherapy for males with an IPSS-V/S of 1 is safe and effective. The IPSS may be used to
evaluate female LUTD. The IPSS-V/S was found to have the highest area under the receiver-operating
characteristic curve for predicting voiding LUTD when compared with other noninvasive methods.
This ratio is also a useful indicator to initiate treatment of voiding dysfunction in women.
Copyright © 2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Lower urinary tract symptoms (LUTS) include voiding, storage,
and postmicturition symptoms [1]. LUTSmay result from a complex
interplay of the pathophysiological features of bladder dysfunction
and bladder outlet dysfunction, e.g., benign prostatic obstruction
(BPO), bladder neck dysfunction, and poor relaxation of the ure-
thral sphincter [2]. Treatment of LUTS in men depends on the eti-
ology of symptoms. Traditionally, LUTS in men has been attributed
to BPO and is treated with a-blockers [3]. However, men who
receive treatment for prostate conditions may have persistent
storage symptoms [4,5]; recent studies have indicated a shift from
the prostate to the bladder as a potential source of LUTS [3].Buddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
elief Tzu Chi Foundation. PublisheCurrent guidelines suggest that antimuscarinic monotherapy
can be used for men with storage LUTS who do not have voiding
LUTS or bladder outlet obstruction (BOO). Combination therapy is
recommended for men with concomitant BOO and an overactive
bladder, if symptom relief has been insufﬁcient after monotherapy
for either disorder [6e9]. However, the presence and degree of BOO
may be difﬁcult to determine without a pressure ﬂow study. The
symptom score, urine ﬂow rate, and total prostate volume (TPV) are
commonly used, but these parameters are poor predictors of BOO
when used alone [3,10]. In addition, there are still no deﬁnitive
criteria to determine whether a patient should receive anti-
muscarinic monotherapy or combination therapy.
2. International Prostate Symptom Score voiding-to-storage
subscore ratio
The International Prostate Symptom Score (IPSS) consists of
seven questions that are used to assess voiding symptoms
(incomplete emptying, intermittency, weak stream, and straining
to void) and storage symptoms (frequency, urgency, and nocturia)d by Elsevier Taiwan LLC. All rights reserved.
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the severity of LUTS/BPO and other conditions that cause LUTS.
However, the total IPSS (IPSS-T) correlates poorly with BOO and
overactive bladder, and is unreliable for establishing a deﬁnitive
diagnosis [10]. Although the clinical symptoms are not always
reliable for establishing a diagnosis, patients with bladder outlet-
related lower urinary tract disease (LUTD) tend to have more
prominent voiding symptoms, whereas those with bladder-related
LUTD tend to have more prominent storage symptoms.
The IPSS can be subdivided into the IPSS voiding subscore (IPSS-
V) and the IPSS storage subscore (IPSS-S). The IPSS-V is the sum of
the answers to question 1 (incomplete emptying), question 3
(intermittency), question 5 (weak stream), and question 6 (strain-
ing to void). By contrast, the IPSS-S is the sum of the answers to
question 2 (frequency), question 4 (urgency), and question 7
(nocturia). The IPSS subscore can be used to evaluate symptom
severity or the results of treatment. However, it is difﬁcult to use
the IPSS subscore as a diagnostic tool because of the overlap be-
tween bladder-related and bladder outlet-related LUTD.
3. Using the IPSS-V to IPSS-S ratio to evaluate male LUTS prior
to initiating drug therapy
Liao et al [12] reported a retrospective study of 253 men with
LUTS. Each patient was investigated with video urodynamics to
make a deﬁnitive diagnosis. The various diagnoses included idio-
pathic detrusor overactivity (DO), increased bladder sensitivity,
detrusor hyper-reﬂexia and impaired contractility, urethral stric-
ture, BPO, bladder neck dysfunction, and poor relaxation of the
urethral sphincter. Patients with bladder outlet-related LUTD had a
signiﬁcantly higher IPSS-VeIPSS-S ratio (IPSS-V/S) than those with
bladder-related LUTD. Although patients with combined BPO and
DO had a signiﬁcantly lower IPSS-V/S than those with BPO and no
DO, their average IPSS-V/S was still higher than those with DO
alone.
The IPSS-V and IPSS-S of each patient, obtained from the study
of Liao et al [12], were plotted, with the IPSS-V on the vertical axisFig. 1. IPSS-V (vertical axis) and IPSS-S (horizontal axis) of each patient, as obtained
from the study of Liao et al [12], are plotted. A line (IPSS V/S ¼ 1) has been drawn to
differentiate patients with bladder-related LUTD from those with bladder outlet-
related LUTD. The IPSS-V to IPSS-S ratio (IPSS-V/S) of each patient was calculated
and used as a potential diagnostic indicator. BPH ¼ benign prostatic hyperplasia;
IPSS ¼ International Prostate Symptom Score; IPSS-S ¼ IPSS storage subscore; IPSS-
V ¼ IPSS voiding subscore; LUTD ¼ lower urinary tract disease; OAB ¼ overactive
bladder.and the IPSS-S on the horizontal axis (Fig. 1). A line (IPSS-V/S ¼ 1)
was drawn to differentiate patients with bladder-related LUTD
from those with bladder outlet-related LUTD. The IPSS-V/S of each
patient was calculated and used as a potential diagnostic indicator.
The area under the receiver-operating characteristic curve was
used to evaluate the diagnostic value of various noninvasive
methods for predicting failure to void (bladder outlet-related) and
failure to store (bladder-related) LUTD. The IPSS-V/S was a better
predictor than the IPSS-T, IPSS-V, IPSS-S, maximal ﬂow rate (Qmax),
postvoid residual (PVR), and TPV. An IPSS-V/S with a cutoff value of
1 had a high sensitivity and acceptable speciﬁcity. Bladder-related
LUTD was found in 75.7% of patients with an IPSS-V/S of 1,
whereas bladder outlet-related LUTDwas found in 81.2% of patients
with an IPSS-V/S of >1 [12].
4. Diagnosis using the IPSS-V/S combined with TPV and Qmax
In one study, the combination of a TPV of 30 mL and a Qmax of
10 mL/second had a positive predictive value (PPV) of 68.8% and a
negative predictive value (NPV) of 53.5% for bladder outlet-related
LUTD.When an IPSS-T of12 or an IPSS-T of15 was considered as
an additional criterion, the PPV increased to 75.0% and 78.5%,
respectively, and the NPV decreased to 50.9% and 50.2%, respec-
tively. When an IPSS-V/S of >1 or >2 was factored into the equation
instead of the IPSS-T, the PPVwas 91.4% and 97.3%, respectively, and
the NPVwas 54.8% and 49.8%, respectively [13]. We suggest that the
IPSS-V/S combined with the TPV and Qmax results in a higher PPV
than the IPSS-T.
5. Treatment based on the IPSS-V/S
The IPSS-V/S may serve as an indicator to initiate treatment for
male patients with LUTS. A prospective study was conducted to
investigate treatment results based on the IPSS-V/S [14]. First-line
doxazosin and tolterodine monotherapy were given to patients
with an IPSS-V/S of >1 and IPSS-V/S of 1, respectively. After
medical treatment for 1 month, 76.7% of patients administered
tolterodine and 78.1% administered doxazosin reported an
improved outcome (global response assessment 1 point). No pa-
tient developed urinary retention after tolterodine monotherapy
for 1 month. However, patients older than 70 years were more
likely to have an increased PVR (50 mL). Combination therapy or
change to another medication may be considered if ﬁrst-line
treatment fails.
6. Safety of ﬁrst-line treatment with antimuscarinics in
patients with an enlarged prostate
Traditionally, antimuscarinics have been contraindicated in pa-
tients with an enlarged prostate. Although several studies have
reported the safety of antimuscarinics in males with no elevated
PVR (200e250 mL), there is often a concern that the inhibitory
effect of antimuscarinics may aggravate voiding difﬁculties or cause
urinary retention [15,16]. To examine the safety of ﬁrst-line anti-
muscarinics in patients with an enlarged prostate, another pro-
spective open-label study, enrolling men with an IPSS-T of 8, a
TPV of 20 mL, an IPSS quality-of-life index of 2, an IPSS-V/S of
1, and a PVR of 250 mL, was conducted [17]. First-line anti-
muscarinics improved symptoms and quality of life for 12 weeks.
Around 10% of patients complained of dysuria, and the average PVR
increased signiﬁcantly, to around 20 mL. However, no urinary
retention developed. Regression analyses showed that the baseline
Qmax, baseline IPSS-S, and TPV were predictors of successful anti-
muscarinic monotherapy.
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The IPSS can also be used to evaluate female LUTD. Okamura
et al [18] performed psychometric analysis of the IPSS for female
LUTS. The reliability and validity of the IPSS for female LUTS was
tested. They concluded that the IPSS can be relevant when used to
examine women, as it is in men. The IPSS has also been used in
several epidemiological studies to evaluate the prevalence of fe-
male LUTS and voiding dysfunction [19,20]. On and Ku [21] re-
ported a comparative study of IPSS and urodynamic parameters in
men and women with LUTS. The IPSS-V was higher in men,
whereas the Qmax was higher in women. Multiple linear regression
analysis identiﬁed that frequency possibly explained a reduction in
the quality of life in elderly women.
Hsiao et al [22] investigated the feasibility of using the IPSS and
IPSS-V/S to evaluate female LUTS. They reported that signiﬁcantly
higher IPSS-V/S and IPSS-V were found in those with voiding
dysfunction. The IPSS-V/S was found to have the highest area under
the receiver-operating characteristic curve for predicting voiding
LUTD, when compared with other noninvasive methods. An IPSS-V/
S of 1.33 had the best predictive value for female voiding LUTD
with a high NPV (97.4%). The IPSS-V/S may provide an initial guide
for the treatment of voiding dysfunction inwomen. In addition, the
IPSS-S may be used for evaluating storage LUTD in women.
One problem, reported by Coyne et al [23], is that the LUTS that
are excluded from the IPSS, most notably incontinence, are preva-
lent even among mildly symptomatic participants. They suggested
that because storage symptoms appear to drive treatment seeking,
identifying, and treating these symptoms are essential when caring
for patients with LUTS.
8. Conclusion
LUTS may involve bladder dysfunction and bladder outlet dis-
orders. Treatment should be based on the most likely etiology.
Medication may be given to relieve outlet resistance and decrease
bladder sensation or DO. The use of IPSS subscores and calculation
of the IPSS-V/S can help differentiate between bladder- and bladder
outlet-related LUTD. The IPSS-V/S is a better predictor of bladder
outlet-related LUTD than the IPSS-T, whether used alone or in
combination with the TPV and Qmax. The IPSS-V/S can also be used
as a guide for the initial treatment of male LUTS, especially by
nonurologists. First-line antimuscarinic monotherapy for males
with an IPSS-V/S of 1 is safe and effective. The IPSS can also be
used to evaluate female LUTD. The IPSS-V/S was found to have the
highest area under the receiver-operating characteristic curve for
predicting voiding LUTD, when compared with other noninvasive
methods. This ratio may also provide an initial guide for the
treatment of voiding dysfunction in women.
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